Reversal of multidrug resistance by methoxypolyethylene glycol-block-polycaprolactone diblock copolymers through the inhibition of P-glycoprotein function

Journal of Pharmaceutical Sciences

Volumn 98, Issue 3, 2009, Pages 945-958

  Elamanchili, Praveen ^a   Mceachern, Cyrus ^a   Burt, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Diblock copolymers; Micelle; Multidrug resistance; P glycoprotein; Polymeric drug delivery systems; Surfactants

Indexed keywords

COPOLYMER; DOXORUBICIN; GLYCOPROTEIN P; METHOXYPOLYETHYLENE GLYCOL BLOCK POLYCAPROLACTONE DIBLOCK SOPOLYMER; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL CELL; ARTICLE; BIOACCUMULATION; CANCER CELL; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG UPTAKE; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

EID: 62849118492     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21479     Document Type: Article

References (40)

1. Naito S, Yokomizo A, Koga H. 1999. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol 6:427-439.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. 2006. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219-234.
3. Krishan A, Fitz CM, Andritsch I. 1997. Drug retention, efflux, and resistance in tumor cells. Cytometry 29:279-285.
4. Krishna R, Mayer LD. 2000. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 11:265-283.
5. Omote H, Al-Shawi MK. 2006. Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism. Biophys J 90:4046-4059.
6. Higgins CF, Gottesman MM. 1992. Is the multidrug transporter a flippase? Trends Biochem Sci 17: 18-21.
7. Loo TW, Clarke DM. 2005. Do drug substrates enter the common drug-binding pocket of P-glycoprotein through "gates"? Biochem Biophys Res Commun 329:419-422.
8. Higgins CF, Linton KJ. 2004. The ATP switch model for ABC transporters. Nat Struct Mol Biol 11:918-926.
9. Lum BL, Gosland MP, Kaubisch S, Sikic BI. 1993. Molecular targets in oncology: Implications of the multidrug resistance gene. Pharmacotherapy 13:88-109.
10. Hugger ED, Novak BL, Burton PS, Audus KL, Borchardt RT. 2002. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 91:1991-2002.
11. Riehm H, Biedler JL. 1972. Potentiation of drug effect by Tween 80 in Chinese hamster cells resistant to actinomycin D and daunomycin. Cancer Res 32:1195-1200.
12. Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, Arjakov SA, Alakhov VY, Kabanov AV. 1996. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: In vivo evaluation of anti-cancer activity. Br J Cancer 74:1545-1552.
13. Alakhov V, Moskaleva E, Batrakova EV, Kabanov AV. 1996. Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug Chem 7:209-216.
14. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. 1996. Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626-3629.
15. Regev R, Katzir H, Yeheskely-Hayon D, Eytan GD. 2007. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane. FEBS J 274:6204-6214.
16. Seelig A, Gerebtzoff G. 2006. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol 2:733-752.
17. Burt HM, Zhang X, Toleikis P, Embree L, Hunter WL. 1999. Development of copolymers of poly(D,L-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids Surf B: Biointerf 16:1-4.
18. Shuai X, Ai H, Nasongkla N, Kim S, Gao J. 2004. Micellar carriers based on block copolymers of poly-(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release 98:415-426.
19. Letchford K, Burt H. 2007. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65:259-269.
20. Letchford K, Liggins R, Burt H. 2008. Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: Theoretical and experimental data and correlations. J Pharm Sci 97:1179-1190.
21. Zastre J, Jackson J, Bajwa M, Liggins R, Iqbal F, Burt H. 2002. Enhanced cellular accumulation of a P-glycoprotein substrate, rhodamine-123, by Caco-2 cells using low molecular weight methoxypolyethylene glycol-block- polycaprolactone diblock copolymers. Eur J Pharm Biopharm 54:299-309.
22. Kabanov AV, Batrakova EV, Alakhov VY. 2002. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54:759-779.
23. Liscovitch M, Ravid D. 2007. A case study in misidentification of cancer cell lines: MCF-7/AdrR cells (re-designated NCI/ADR-RES) are derived from OVCAR-8 human ovarian carcinoma cells. Cancer Lett 245:350-352.
24. Hunter J, Hirst BH, Simmons NL. 1993. Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers. Pharm Res 10:743-749.
25. Johnson BM, Charman WN, Porter CJ. 2002. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm Sci 4:E40.
26. Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G. 2004. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278:119-131.
27. Shen Q, Lin Y, Handa T, Doi M, Sugie M, Wakayama K, Okada N, Fujita T, Yamamoto A. 2006. Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 313:49-56.
28. Dintaman JM, Silverman JA. 1999. Inhibition of P-glycoprotein by D-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 16:1550-1556.
29. Zastre JA, Jackson JK, Wong W, Burt HM. 2008. P-Glycoprotein efflux inhibition by amphiphilic diblock copolymers: Relationship between copolymer concentration and substrate hydrophobicity. Mol Pharm (in press).
30. Sognier MA, Zhang Y, Eberle RL, Belli JA. 1992. Characterization of adriamycin-resistant and radiation-sensitive Chinese hamster cell lines. Biochem Pharmacol 44:1859-1868.
31. Gatlik-Landwojtowicz E, Aanismaa P, Seelig A. 2006. Quantification and characterization of P-glycoprotein-substrate interactions. Biochemistry 45:3020-3032.
32. Zastre J, Jackson JK, Wong W, Burt HM. 2007. Methoxypolyethylene glycol-block-polycaprolactone diblock copolymers reduce P-glycoprotein efflux in the absence of a membrane fluidization effect while stimulating P-glycoprotein ATPase activity. J Pharm Sci 96:864-875.
33. Zhang X, Burt HM, Von Hoff D, Dexter D, Mangold G, Degen D, Oktaba AM, Hunter WL. 1997. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol 40:81-86.
34. Millenbaugh NJ, Wientjes MG, Au JL. 2000. A pharmacodynamic analysis method to determine the relative importance of drug concentration and treatment time on effect. Cancer Chemother Pharmacol 45:265-272.
35. Chavanpatil MD, Patil Y, Panyam J. 2006. Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux. Int J Pharm 320:150-156.
36. Dorr RT. 1998. Antineoplastics, chemoprotectants and immunosuppresants. In: Anderson PO, Knoben JE, editors. Handbook of clinical drug data. East Norwalk, CT: Appleton & Lange. pp. 157-212.
37. Eksborg S. 1978. Extraction of daunorubicin and doxorubicin and their hydroxyl metabolites: Self-association in aqueous solution. J Pharm Sci 67: 782-785.
38. Baldini N, Scotlandi K, Serra M, Shikita T, Zini N, Ognibene A, Santi S, Ferracini R, Maraldi NM. 1995. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution. Eur J Cell Biol 68:226-239.
39. Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. 2003. Optimal structure requirements for pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 304:845-854.
40. Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. 2001. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: Selective energy depletion. Br J Cancer 85:1987-1997.